Bick Remmey

When evaluating eIRB systems, be sure to consider the needs of ALL institutional stakeholders - not just the IRB users. Read our blog from Advarra expert Faith Bertrand, CIP for advice bon assessing and implementing these technologies.

5

A big thank you to HBA NY Tri-State region's Central NJ chapter and Sanofi for hosting an exceptional event on market access in the pharmaceutical industry. The panel did an outstanding job educating attendees on the crucial role market access plays within pharma organizations. 📝 Key takeaways⭐️: 📓Commit to learning: If you're considering market access as part of your career path, don't just dip your toes in. Dedicate 2-3 or more years or more to truly understand the field's complexities. ❓Cultivate curiosity: Success in market access hinges on asking the right questions. Develop a mindset of continuous inquiry to excel in this role. 🏃‍♂️‍➡️Stay adaptable: The market access landscape evolves rapidly. Be prepared to keep learning and adjusting your strategies as the field changes. This event reinforced the importance of market access in shaping the future of pharmaceutical companies and patient care. Negelle Morris Nazanin Mehin Olivier Bogillot Garrett Ingram Lalitha P. Chandrashekhar #MarketAccess #Pharma #ProfessionalDevelopment #HBACentralNJ #Sanofi

111

4 Comments

Check out this white paper "Digital Transformation and Paperless CQV" by Azzur Vice President of Consulting Services, Brijesh Patel, where he provides innovative CQV insights and recommendations. Link in comments

1

1 Comment

🚀 BIOPROCESSING SUMMIT 📅 Monday August 19, 12:00 PM 📍Gene Therapy CMC and Analytics Track Do not miss the opportunity to visit my Luncheon Presentation during the #CHIBioprocessingSummit in Boston: 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗲𝗱 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 𝗧𝗵𝗲 𝗠𝗮𝗸𝗶𝗻𝗴-𝗢𝗳 𝗗𝗘𝗡𝗔𝗥𝗔𝗦𝗘 𝗛𝗶𝗴𝗵 𝗦𝗮𝗹𝘁 𝗳𝗼𝗿 𝗛𝗶𝗴𝗵-𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗗𝗡𝗔 𝗥𝗲𝗺𝗼𝘃𝗮𝗹 𝗶𝗻 𝗩𝗶𝗿𝗮𝗹 𝗩𝗲𝗰𝘁𝗼𝗿 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 👇Session Objectives: 🔎 How to improve efficiency of viral vector manufacturing at elevated salt concentrations ✅ The benefits of DENARASE High Salt for DNA removal 🔬 Enzyme engineering at c-LEcta: ENESYZ Technology Platform 📣 Stop also by 𝗕𝗼𝗼𝘁𝗵 𝟱𝟬𝟳 to talk to my colleagues Tim McClain, Jay Lachance and Elena Kempf who will tell you more about 𝗗𝗘𝗡𝗔𝗥𝗔𝗦𝗘 𝗛𝗶𝗴𝗵 𝗦𝗮𝗹𝘁 and our complete toolkit for DNA removal. Cambridge Healthtech Institute #CGT #DENARASE #biopharma #ISCT2024 #enzyme #endonuclease #viralvector #bioprocessing

27

With Mental Health America, we're humbled to announce the launch of the new Equity Impact Zone (EIZ) grant program designed to address mental health equity gaps within local New Jersey communities. Understanding that factors such as housing, income, food security, safety, and freedom from discrimination are known to be key social drivers of mental health inequity, the mission of the EIZ program is to empower community-based organizations to implement resources tailored to the unique needs of their members. Recipients of the inaugural grants are Young Audiences (YA) New Jersey & Eastern Pennsylvania in Burlington County, and the Mental Health Association of New Jersey (MHANJ) in Trenton. At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere. Read more about the recipients: https://lnkd.in/e4kZ6GV3

5

I recently moderated a discussion with experts from the University of Nebraska Medical Center, CSIRO’s Data61, and Realyze Intelligence on the integration of artificial intelligence in clinical trials. We explored how AI can boost efficiency, promote equity, streamline patient recruitment, and enhance trial design. Despite the challenges, the potential benefits of AI are substantial. If you missed the live stream, you can now watch the recap and recording. https://lnkd.in/ewmnygNF

25

What is driving investment in the life sciences sector? JLL Executive Managing Director of Life Sciences Grant Schoneman discussed life sciences trends, including record number of FDA approvals and new capital, and what is expected to influence the sector through the remainder of the year. Click the link to learn more. #jLLLifeSciences #LifeSciences

7

If you've yet to download the CRB Horizons report you're missing out on a wealth of free information that will inform you, your company, facility, and projects now and into the future!

20

The choice of data can make or break your RWE study. Claims, EMRs, registries, surveys—each has its strengths, but aligning the right dataset with your goals is where the real impact lies. 🔍 Our latest white paper helps you focus on the questions that matter: - What’s my study’s goal, and which data supports it best? - How do healthcare systems in the US and Japan shape my approach? - Where are the gaps, and how can linked datasets fill them? 💡 Great research starts with asking the right questions—and acting on the answers. ✨ Start your 2025 RWE strategy strong. Download: https://lnkd.in/eDHfDaau hashtag #RealWorldEvidence #DataDecisions #RWE

2

Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA

6

Let's connect to review the latest from our KMR Benchmarking & Analytics team - see how you stack up against industry peers and explore ideas for operational improvement.

19

1 Comment

Recently, our team at UPMC Enterprises hosted the second annual Top of Mind Summit: Life Sciences at the Center for Connected Medicine at UPMC, bringing together leaders from health care, biotechnology, policy, pharma, and life sciences for transformative discussions on accelerating health care models with technological innovation, patient-centered care, and strategic collaborations. During the event, I joined leaders from Memorial Hermann Health System, UPMC Health Plan, and the Arctos Foundation for a keynote discussion focused on the escalating costs of novel therapeutics and the need for sustainable reimbursement models. For insights from our panel, “The Evolving Health Care Landscape,” along with additional highlights from the summit, you can access the recap report here. https://lnkd.in/e-KHJYMW

86

1 Comment

An IRB can review a "minor" study change via expedited review - but the regulations don't really define what "minor" means. Find out how IRBs navigate this grey area in our blog:

3

Networking and learning are important regardless of what stage you’re at in your career. Looking forward to reconnecting with colleagues and meeting new colleagues. Hope to see you at Northeast AMCP Day of Learning October 4th in NYC! #networking #continouslearning #everydayleadership #extraordinaryYOU

3

CERTAINTY 2025! Save the date for another great meeting of the minds! #certainty #certara #modelinformeddrugdevelopment #drugdevelopment #AI #regulatorywriting #regulatorysubmissions #clinicalpharmacology

16

Looking forward to conversations around therapies and technology progressing with improved investor sentiment, albeit with caution! Investing? How commercially viable is the science? What are the product development/CMC and regulatory/clinical risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! Let’s connect and discuss how Boyds can help! #REAIBoston2024 #BiotechweekBoston

22

The fourth quarter of 2024 is critical for the biotech industry, with 5 major FDA approval decisions on the horizon. These upcoming verdicts could impact everything from treatments for cancer to rare diseases. 🧬 Stay ahead of the latest in biotech and learn how these FDA decisions could shape the future of healthcare.

1

Our team at UPMC Enterprises recently brought together an exceptional group of industry leaders from health care, biotechnology, policy, pharma, and life sciences for the second annual Top of Mind Summit: Life Sciences.  This year’s Summit fostered transformative discussions and meaningful collaboration on technological innovation, life-changing health care models, patient-centered care, and strategic partnerships. We invited forward-thinking professionals to address the pressing challenges and emerging opportunities shaping the future of health care. Key topics included how real-world data and AI are reshaping therapeutic development, what is needed to optimize clinical trials, and how we can enhance equitable access to cutting-edge treatments. Panels also highlighted the essential role of partnerships across health care systems, academia, and industry, with a special pre-summit on women’s health that built crucial networks to advance the health of women. At the Summit, we showcased UPMC’s distinctive approach to innovation and the unique UPMC Enterprises model, which merges clinical and scientific insights with investment discipline and industry knowledge to drive progress. I was honored to help lead the event and two of the discussions. We’re excited to share highlights and impactful moments from the Summit with you in the recap report. Let’s continue building on these conversations and partnerships to create a stronger, more innovative health care ecosystem. https://lnkd.in/eHnmaAAq

46